FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Multiple Adept Medical Violations Cited

[ Price : $8.95]

FDA warns Auckland, New Zealand-based Adept Medical about Quality System and other violations in its production of ventilation tub...

CGMP Violations at Italys Eurosirel

[ Price : $8.95]

FDA warns Milan, Italy-based Eurosirel about CGMP violations in its production of finished drugs.

Oncologic Drugs Ovarian Toxicity Guidance

[ Price : $8.95]

FDA publishes a draft guidance with recommendations to oncologic drug sponsors about measuring ovarian toxicity in relevant clinic...

Court Tosses Attorneys Privacy Suit Against FDA

[ Price : $8.95]

The DC federal court agrees with FDA that a suit against the agency over identifying an attorney in a regulated company on a form ...

Satsuma Pharma NDA Resubmission for Migraine Drug

[ Price : $8.95]

FDA accepts for review a Satsuma Pharmaceuticals NDA resubmission for STS101 (dihydroergotamine nasal powder) for the acute treatm...

Axsome to File NDA on Narcolepsy Drug

[ Price : $8.95]

Based on just-reported Phase 3 trial data, Axsome Therapeutics says it will submit an NDA for on AXS-12 (reboxetine) and its use i...

Follow-up Testing for Ames-Positive Drugs: Guide

[ Price : $8.95]

FDA posts a draft guidance entitled Recommended Follow-Up Testing for an Ames-Positive Drug (Active Ingredient) or Metabolite To S...

6 Observations on Regeneron FDA-483

[ Price : $8.95]

FDA releases the form FDA-483 with six observations from an inspection at Limerick, Ireland-based Regeneron Ireland Designated Act...

Alnylam Files sNDA for Vutrisiran

[ Price : $8.95]

FDA accepts for review an Alnylam Pharmaceuticals supplemental NDA for vutrisiran, an investigational RNAi therapeutic in developm...

BridgeBio Gets Transthyretin Amyloidosis Drug OK

[ Price : $8.95]

FDA approves a BridgeBio Pharma NDA for Attruby (acoramidis), a near-complete stabilizer of transthyretin for treating adults with...